The Union Health Ministry has proposed a separate licensing regime for the wholesale sale of bulk drugs, seeking to tighten regulatory oversight, improve accountability and strengthen control over the pharmaceutical supply chain.
The proposed amendments to the Drugs Rules, 1945, notified through a Draft Gazette Notification, introduce a dedicated application form (Form 19-BC) and licence form (Form 20-BC) for the wholesale sale of bulk drugs, including active and inactive bulk substances.
Currently, wholesalers can sell both pharmaceutical formulations and bulk drugs under a common licence. The proposed changes seek to end this arrangement by creating a separate licensing framework specifically for bulk drugs.
The move is aimed at bringing greater regulatory scrutiny to bulk drug distribution and ensuring clearer accountability among wholesalers handling these substances.
The proposal has received the approval of the Drugs Consultative Committee (DCC) at its 67th meeting on November 17, 2025, and the Drugs Technical Advisory Board (DTAB) at its 93rd meeting on February 16, 2026.
Under the proposed framework, wholesalers will have to specify the categories of bulk drugs they intend to handle under their licences. This will include substances covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.
The amendments also propose that bulk drug sales be conducted under the personal supervision of a competent person, placing greater responsibility on wholesalers for the handling and distribution of these substances.
The government expects the proposed framework to deliver tighter control over bulk drug sales, strengthen enforcement against the misuse and unauthorised movement of NDPS-regulated drugs, and improve oversight of antimicrobial distribution in the context of antimicrobial resistance.
A separate licence will become mandatory for wholesalers dealing in bulk drugs once the amendments are implemented.
However, existing licensees will get time to transition to the new regulatory regime. The revised requirements will apply to them upon the expiry of their current retention period or 12 months after the final publication of the amendment, whichever is later.
The proposed changes mark a move towards a more targeted regulatory framework for bulk drug distribution, with the government seeking tighter supervision of a critical segment of the pharmaceutical supply chain.